LLY•benzinga•
Eli Lilly's Cholesterol Drug Reduces Genetic Heart Disease Risk Factor By 93.9%
Summary
Eli Lilly's lepodisiran met Phase 2 trial goals, significantly lowering Lp(a) levels. A Phase 3 study is enrolling to assess its impact on cardiovascular events.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 31, 2025 by benzinga